ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,458,637, issued on Nov. 4, was assigned to Kobenhavns Universitet (Copenhagen K, Denmark).
"Targeting WNK1 in blood cancers" was invented by Kristian Helin (Copenhagen N, Denmark) and Karl Agger (Copenhagen N, Denmark).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to lysine deficient protein kinase 1 (WNK1) inhibitors for use in treating patients with blood cancers, in particular leukemia and multiple myeloma."
The patent was filed on Aug. 11, 2020, under Application No. 17/633,905.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF...